A study examined the consequences of an FDA warning recommending against the prescription of the antidepressant citalopram at dosages higher than 40 mg/day.
A study examined the consequences of an FDA warning recommending against the prescription of the antidepressant citalopram at dosages higher than 40 mg/day.
A study examined the consequences of an FDA warning recommending against the prescription of the antidepressant citalopram at dosages higher than 40 mg/day.
The FDA has issued a warning of serious and potentially fatal cardiac problems associated with the higher-than-recommended use of the antidiarrheal drug loperamide (Imodium).
The FDA has issued a warning of serious and potentially fatal cardiac problems associated with the higher-than-recommended use of the antidiarrheal drug loperamide (Imodium).
The FDA has issued a warning of serious and potentially fatal cardiac problems associated with the higher-than-recommended use of the antidiarrheal drug loperamide (Imodium).
Primary care practitioners should be aware of 3 new FDA approvals that may be useful when treating patients with opioid dependence, prostate cancer, and multiple sclerosis.
A safety review showed that when fluoroquinolones were used systemically, they were associated with disabling and potentially permanent serious adverse effects.
A safety review showed that when fluoroquinolones were used systemically, they were associated with disabling and potentially permanent serious adverse effects.
A safety review showed that when fluoroquinolones were used systemically, they were associated with disabling and potentially permanent serious adverse effects.
